Haleon plc (LON:HLN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Haleon plc (LON:HLN) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is GBX 407.

HLN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft cut their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Berenberg Bank boosted their price objective on Haleon from GBX 510 to GBX 512 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 450 price objective on shares of Haleon in a research note on Monday, March 30th.

Haleon Price Performance

LON:HLN opened at GBX 373.70 on Tuesday. Haleon has a 12 month low of GBX 325.10 and a 12 month high of GBX 419.50. The stock has a 50 day moving average of GBX 385.76 and a two-hundred day moving average of GBX 368.32. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The firm has a market cap of £33.28 billion, a P/E ratio of 20.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last posted its quarterly earnings data on Thursday, February 26th. The company reported GBX 18.60 EPS for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. On average, analysts expect that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Insider Buying and Selling at Haleon

In other news, insider Brian McNamara sold 704,974 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £2,594,304.32. 0.02% of the stock is currently owned by corporate insiders.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.